Rainer StrohmengerManaging Partner at Wellington Partners
With over 20 investments in start-up companies, Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His more than 20 years of investment activity have involved financing of some of the most successful European biotech, medtech, diagnostics and healthcare IT companies.
In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, which became the most successful venture-backed biopharmaceutical company in Europe and was acquired in 2017 by Johnson & Johnson for US$ 30 billion. He was also responsible for the investments in Grandis (acquired by Novartis), invendo medical (acquired by Ambu), NoemaLife (Borsa Italiana:NOE), Wavelight (acquired by Alcon), Oxford Immunotec (NASDAQ: OXFD), Genkyotex (NYSE Euronext: GKTX), Definiens (acquired by Medimmune), immatics as well as mtm laboratories (acquired by Roche).
Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany.